Guardant Health, Inc. products

Our Guardant360® CDx test is FDA-approved for complete genomic testing across all solid cancers, providing doctors guideline-complete genomic results in 7 days from a simple blood draw to inform treatment decisions. A blood test does not require tissue testing, enabling more patients to benefit from the growing number of FDA-approved targeted therapies. Starting with the Guardant360 CDx test for complete genomic profiling identifies more patients with actionable biomarkers more quickly than starting with tissue biopsy.1-3 The test covers all genes recommended by the National Comprehensive Cancer Network, including the 55 most relevant to clinical care. The test is also approved as a companion diagnostic to identify patients with non-small cell lung cancer who may benefit from treatment with TAGRISSO® (osimertinib), RYBREVANT™ (amivantamab-vmjw), and LUMAKRAS™ (sotorasib).

The Guardant Reveal™ test is the first blood-only liquid biopsy test that detects residual and recurrent disease in 7 days from a simple blood draw. The test detects any circulating tumor DNA (ctDNA) in blood after surgery to identify patients with residual disease who may benefit most from adjuvant therapy, and detects recurrence months earlier than current standard-of-care methods like carcinoembryonic antigen (CEA) tests or imaging. The commercially available test achieves industry-leading sensitivity (91%)7 for correctly detecting ctDNA and enables biopharma companies and academic researchers to identify new drug development opportunities to serve patients. The first indication of the test is early-stage CRC with additional cancer types to follow.